Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as veltuzumab, IMMU-106, hA20
hA20-humanized anti-CD20 antibody · 3 trials · 21 indications
safety will be assessed by monitoring lab results and adverse events, which will be assessed every 3 months for up to 2 years.
| Arm | Type | Description |
|---|---|---|
| veltuzumab | EXPERIMENTAL | veltuzumab is a humanized CD20 antibody administered subcutaneously in this study. |
| Dose level 1 | EXPERIMENTAL | 120 mg/m2 |
| Dose level 2 | EXPERIMENTAL | 200 mg/m2 |
| Dose Level 3 | EXPERIMENTAL | 375 mg/m2 |
| Dose level 1B | EXPERIMENTAL | 80 mg/m2 |
| Name | Type | Description |
|---|---|---|
| veltuzumab | BIOLOGICAL | veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks. |
| hA20-humanized anti-CD20 antibody | DRUG | once weekly iv dosing for 4 weeks |
Inclusion Criteria: * Histologically confirmed diagnosis of CD20 positive chronic lymphocytic leukemia (CLL) * Either previously untreated or relapsed * Measurable disease (at least one lesion \> 1.5 cm for NHL, or ALC \> 5,000 for CLL) see full protocol for additional criteria Exclusion Criteria:...
hA20 is a humanized anti-CD20 antibody being developed by Gilead Sciences, Inc. (ticker: GILD) for the treatment of CD20-positive non-Hodgkin's lymphoma. It is an investigational therapy that has been studied in a Phase 1 clinical trial. The drug targets the CD20 antigen found on B cells.
hA20 is being studied for use in patients with CD20-positive non-Hodgkin's lymphoma. The Phase 1 trial enrolled 82 patients aged 18 years and older in the United States. It is an investigational agent and has not been approved for commercial use.
hA20 targets the CD20 antigen, a protein found on the surface of B cells. By binding to CD20, the antibody is designed to act against CD20-positive B-cell lymphomas. The trial specifically enrolled patients with CD20+ non-Hodgkin's lymphoma, indicating the therapy is biomarker-selected for CD20 expression.
hA20 is being developed by Gilead Sciences, Inc., which trades on the Nasdaq under the ticker GILD. Gilead is the sponsor of the clinical program evaluating this humanized anti-CD20 antibody in non-Hodgkin's lymphoma.
hA20 is in Phase 1 clinical development. The single Phase 1 trial, NCT00285428, has been completed and enrolled 82 patients. The drug is investigational and has not been approved by the FDA for any indication.
hA20 has been evaluated in one completed Phase 1 trial, NCT00285428, titled "Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma." The trial enrolled 82 patients in the United States and included a controlled design. No active trials are currently listed for this agent.